Patient-reported outcome measures (PROMs) complement oncological endpoints by capturing what matters most to patients. The TrueNTH surgical collaboration presented 1-yr PROMs following robotic prostatectomy using accessible visual formats. We present 5-yr PROMs from the phase 3, international PACE-B trial, which randomised men with localised prostate cancer to stereotactic body radiotherapy (SBRT) or conventionally fractionated radiotherapy (CRT). PROMs are reported from baseline to 5 yr and presented using waffle charts to enable visual alignment with surgical outcomes. At 5 yr, urinary incontinence outcomes were favourable and comparable between SBRT and CRT. Leak-free rates were 64% (164/258) for SBRT and 69% (172/249) for CRT, pad-free rates were 91% (233/257) for SBRT and 90% (225/250) for CRT, and moderate or big urinary leakage problems were reported by only 6% (15/250) for SBRT and 4% (9/244) for CRT. Intercourse-adequate erections declined in both groups from baseline to 5 yr: from 35% (133/374) to 17% (43/250) for SBRT, and from 40% (157/391) to 20% (47/240) for CRT. Moderate or big sexual problems increased in both groups, from 24% (87/367) to 31% (74/242) for SBRT and from 22% (85/382) to 32% (77/238) for CRT. Bowel effects were low and comparable between groups, with moderate or big bowel problems reported by 2% (7/397) at baseline and 5% (12/265) for SBRT at 5 yr, and 2% (9/415) at baseline and 5% (13/253) for CRT at 5 yr. Stool incontinence as a moderate or big problem rose from <1% (1/374) to 2% (4/240) in the SBRT group and from <1% (1/395) to 3% (7/238) in the CRT group.
European urology. 2026 Jul 20 [Epub ahead of print]
Sian Cooper, Jaymini Patel, Caroline Moore, Peter Ostler, Hans van der Voet, Andrew Loblaw, William Chu, Daniel Ford, Shaun Tolan, Suneil Jain, Philip Camilleri, Kiran Kancherla, John Frew, Andrew Chan, Olivia Naismith, John Armstrong, John Staffurth, Alexander Martin, Ian Dayes, Paula Wells, Derek Price, Julia Pugh, Georgina Manning, Stephanie Brown, Stephanie Burnett, Nicholas van As, Emma Hall, Alison C Tree
The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK. Electronic address: ., The Institute of Cancer Research, London, UK., University College London (UCL), Division of Surgery and Interventional Science, London, UK; University College London Hospital, London, UK., Mount Vernon Cancer Centre, Northwood, UK., The James Cook University Hospital, Middlesbrough, UK., Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Durham Regional Cancer Centre, Lakeridge Health, Oshawa, ON, Canada., University Hospitals Birmingham, Birmingham, UK., The Clatterbridge Cancer Centre, Birkenhead, UK., Queen's University Belfast, Belfast, UK., Churchill Hospital, Oxford, UK., University Hospitals of Leicester, Leicester, UK., Freeman Hospital, Newcastle, UK., University Hospitals Coventry and Warwickshire, Coventry, UK., The Royal Marsden Hospital, London, UK., Cancer Trials Ireland and St. Luke's Radiation Oncology Network, St. Luke's Hospital, Dublin, Ireland., Velindre Cancer Centre, Cardiff, UK., Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Department of Oncology, McMaster University, Hamilton, ON, Canada., St. Bartholomew's Hospital, London, UK., Patient and Public Representative, London, UK., The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.